20,482 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Fideuram Intesa Sanpaolo Private Banking S.P.A.

Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 20,482 shares of the biopharmaceutical company’s stock, valued at approximately $8,145,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Root Financial Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $29,000. Ameriflex Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $32,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $36,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $39,000. 92.97% of the stock is owned by institutional investors.

Analyst Ratings Changes

ALNY has been the subject of a number of recent research reports. Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Chardan Capital reaffirmed a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. HC Wainwright reaffirmed a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 5th. Royal Bank Of Canada lowered their target price on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Finally, Truist Financial lowered their target price on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $463.13.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 6,799 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the completion of the transaction, the chief executive officer owned 98,628 shares of the company’s stock, valued at $32,315,464.20. This represents a 6.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total transaction of $528,193.96. Following the completion of the sale, the executive vice president owned 21,860 shares in the company, valued at $6,989,297.80. This trade represents a 7.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 21,255 shares of company stock worth $6,930,337. 0.86% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Up 2.8%

Alnylam Pharmaceuticals stock opened at $294.30 on Wednesday. The stock has a market capitalization of $39.29 billion, a PE ratio of 80.41 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a twelve month low of $284.19 and a twelve month high of $495.55. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The company has a 50 day moving average of $312.56 and a 200-day moving average of $362.08.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business’s quarterly revenue was up 96.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.44) earnings per share. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.